大麻使用对烧伤患者临床结局影响的系统综述
该系统综述检索截至2025年8月的文献,纳入8项研究,样本量64至超30万例,评估烧伤住院患者大麻暴露与死亡、感染、移植成功率、血栓、通气、ICU及住院时间、阿片类使用等结局的关系。大麻暴露与住院死亡率无一致关联,但部分研究报告阿片及抗焦虑药需求增加、伤口感染率更高、ICU停留更长及再手术更多;全国数据库研究则显示调整后死亡率更低但呼吸机相关肺炎、静脉血栓栓塞及ICU时间延长更高。证据受回顾性设计、暴露定义不一致及多物质使用混杂限制。
要点
- 大麻暴露与烧伤住院死亡率无一致关联,但可能增加感染、呼吸及血栓并发症风险。
- 部分单中心分析报告大麻使用者阿片及抗焦虑药需求增加、伤口感染率更高、ICU停留更长。
- 入院大麻阳性应加强并发症监测并个体化疼痛管理。
核心结论
- 大麻暴露不似会恶化烧伤患者生存,但可能易感感染、呼吸及血栓栓塞并发症。
研究设计与样本
- 系统综述检索MEDLINE、Embase、CINAHL及Cochrane数据库自建库至2025年8月,纳入8项研究,样本量64至超30万例住院烧伤患者。
主要发现
- 大麻暴露与住院死亡率无一致关联。
- 部分单中心分析报告阿片及抗焦虑药需求增加、伤口感染率更高、ICU停留更长及再手术更多。
- 全国数据库研究显示大麻使用者调整后死亡率更低,但呼吸机相关肺炎、静脉血栓栓塞及ICU停留延长发生率更高。
- 异质性显著,多物质使用、烧伤严重度及人口学差异影响结局。
临床怎么用
- 入院大麻阳性应提示加强并发症监测并制定个体化疼痛管理方案。
局限性
- 证据受回顾性设计限制。
- 暴露定义不一致。
- 多物质使用混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Burn injuries remain a leading cause of morbidity and mortality worldwide, with survivors often requiring prolonged hospitalization, complex wound care, and intensive rehabilitation. Concurrently, cannabis use has risen substantially in North America and Europe, with recent data showing cannabis use in approximately 16-18% of burn admissions by 2025. Cannabinoids influence pain, immunity, and cardiopulmonary physiology, making their role in burn recovery clinically relevant but poorly defined. METHODS: A systematic review was conducted evaluating cannabis exposure and outcomes in burn patients. MEDLINE, Embase, CINAHL, and Cochrane databases were searched from inception to August 2025. Eligible studies included hospitalized burn patients of any age, with cannabis exposure identified via toxicology, history, or coding, and reported outcomes stratified by cannabis exposure. Outcomes of interest included mortality, infection, graft success, thromboembolism, ventilation, ICU and hospital length of stay, opioid use, discharge disposition, and readmission. RESULTS: Of 1009 studies, eight met inclusion criteria, with sample sizes ranging from 64 to over 300,000 patients. Cannabis exposure was identified via toxicology, history, or coding. Across studies, cannabis was not consistently associated with inpatient mortality. Some single-center analyses reported increased opioid and anxiolytic requirements, higher wound infection rates, longer ICU stays, and more reoperations. National database studies found lower adjusted mortality among cannabis-using patients but higher rates of ventilator-associated pneumonia, venous thromboembolism, and prolonged ICU stays. Heterogeneity was pronounced, with polysubstance use, burn severity, and demographic differences influencing outcomes. CONCLUSION: Overall, cannabis exposure does not appear to worsen survival in burn patients but may predispose to infectious, respiratory, and thromboembolic complications. The evidence base is limited by retrospective design, inconsistent exposure definitions, and confounding from polysubstance use. Cannabis positivity at admission should prompt heightened monitoring for complications and tailored pain management. Future prospective, multicenter studies with detailed exposure characterization and long-term follow-up are needed to clarify cannabis' role in burn recovery and to inform evidence-based analgesic strategies.
引用
- Sara Sheikh-Oleslami SS, Amir Khorrami AK, Anthony Papp AP, et al. The impact of cannabis on clinical outcomes in burn patients: A systematic review. Burns. 2026. PMID: 42854438. doi:10.1016/j.burns.2026.108186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。